Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 3/20 | 0.47 |
| ▸ | ESR1 | P03372 | 2/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | GNG2 | P59768 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21584052 | 0.90 | MAPT (0.40) | PGRESR1CHRM2ADORA3AR | |
| SCHEMBL30550463 | 0.79 | ALDH1A1 (0.39) | CHRM1MEN1KMT2A | |
| SCHEMBL2999364 | 0.79 | ALDH1A1 (0.39) | CHRM1MEN1KMT2A | |
| SCHEMBL23731386 | 0.75 | EGFR (0.40) | CYP19A1POLB | |
| SCHEMBL3000584 | 0.75 | NPC1 (0.39) | MAPTCYP3A4KDM4EMEN1KMT2A | |
| SCHEMBL4371875 | 0.74 | PTGS2 (0.40) | ESR1LMNAMAPTCYP3A4KDM4E | |
| SCHEMBL28702513 | 0.74 | CFD (0.43) | PGRESR1CHRM2ADORA3AR | |
| SCHEMBL9261533 | 0.73 | ALOX15 (0.56) | PGRESR1CHRM2ADORA3AR | |
| SCHEMBL34461299 | 0.72 | PGR (0.43) | PGRESR1CHRM2ADORA3AR | |
| SCHEMBL4255144 | 0.71 | NPC1 (0.38) | MAPTCYP3A4KDM4ESMN1; SMN2GNG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024167922-A2 | HETEROCYCLIC COMPOUNDS AS NRAS INHIBITORS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-08-15 | — | — | WO | disclosed |
| US-7825124-B2 | Indolylmaleimide derivatives | ALBERT RAINER | 2010-11-02 | — | — | US | disclosed |
| US-7786123-B2 | Indolylmaleimide derivatives | ALBERT RAINER | 2010-08-31 | — | — | US | disclosed |
| US-20090318463-A1 | Indolylmaleimide Derivatives | ALBERT RAINER | 2009-12-24 | — | — | US | disclosed |
| EP-1337527-B1 | INDOLYLMALEIMIDE DERIVATIVES AS PROTEIN KINASE C INHIBITORS | NOVARTIS AG (CH) | 2009-10-14 | — | — | EP | disclosed |
| EP-2070921-A1 | Indolylmaleimide derivatives as protein kinase c inhibitors | Novartis Ag (CH) | 2009-06-17 | — | — | EP | disclosed |
| US-20070191401-A1 | Transplant rejection, autoimmune disease, autoimmune disease | ALBERT RAINER | 2007-08-16 | — | — | US | disclosed |
| US-20070184061-A1 | Indolylmaleimide derivatives | ALBERT RAINER | 2007-08-09 | — | — | US | disclosed |
| US-20070155817-A1 | Indolylmaleimide derivatives | ALBERT RAINER | 2007-07-05 | — | — | US | disclosed |
| US-7220774-B2 | Indolylmaleimide derivatives | NOVARTIS AG (CH) | 2007-05-22 | — | — | US | disclosed |
| US-20040053949-A1 | Indolylmaleimide derivatives | ALBERT RAINER (CH) | 2004-03-18 | — | — | US | disclosed |
| US-6645970-B2 | Preventing T-cell mediated acute or chronic inflammatory diseases or disorders, autoimmune diseases, graft rejection or cancer | NOVARTIS AG (CH) | 2003-11-11 | — | — | US | disclosed |
| EP-1337527-A1 | INDOLYLMALEIMIDE DERIVATIVES AS PROTEIN KINASE C INHIBITORS | Novartis AG (CH) | 2003-08-27 | — | — | EP | disclosed |
| US-20030069424-A1 | Indolylmaleimide derivatives | NOVARTIS AG (CH) | 2003-04-10 | — | — | US | disclosed |
| WO-2002038561-A1 | INDOLYLMALEIMIDE DERIVATIVES AS PROTEIN KINASE C INHIBITORS | NOVARTIS AG (CH) | 2002-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318463-A1 | Indolylmaleimide Derivatives | NFATC1, INMT, IDO1 | PGR 3653/4885ESR1 4602/4885CHRM2 2814/4885 |
| US-20070191401-A1 | Transplant rejection, autoimmune disease, autoimmune disease | NFATC1, HLA-DRB1, INMT | PGR 2983/4885ESR1 4630/4885CHRM2 4125/4885 |
| US-20030069424-A1 | Indolylmaleimide derivatives | NFATC1, INMT, IDO1 | PGR 3653/4885ESR1 4602/4885CHRM2 2814/4885 |
| US-20040053949-A1 | Indolylmaleimide derivatives | NFATC1, INMT, IDO1 | PGR 3653/4885ESR1 4602/4885CHRM2 2814/4885 |
| US-20070155817-A1 | Indolylmaleimide derivatives | NFATC1, INMT, IDO1 | PGR 3653/4885ESR1 4602/4885CHRM2 2814/4885 |
| US-20070184061-A1 | Indolylmaleimide derivatives | NFATC1, INMT, IDO1 | PGR 3653/4885ESR1 4602/4885CHRM2 2814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.